

## 7 Effects Eye Cream with REFORCYL®

ID	EYE Care / 700258.0001	ID-No: 001.001
pH-value	6.0-6.5	
Appearance	White, light emulsion	
Product Form	Emulsion based on biomimetic protection complex	
Claims	Anti-Ageing; Moisturising; Soothing; Skin barrier protection; Cold production	

St	Substance	INCI Name USA	% w/w	Manufacturer
1	Water demin.	Water	48.66	several
	Verstatil PC	Phenoxyethanol, Caprylyl Glycol	0.80	Evonik, DE
	Glycerin 85%	Glycerin, Water	2.00	several
2	Keltrol CG-SFT	Xanthan Gum	0.20	CP Kelco, US
	Carbopol Ultrez-10	Carbomer	0.30	Lubrizol, US
3	Myritol 312	Caprylic/Capric Triglyceride	10.00	BASF, DE
	Tegosoft DEC	Diethylhexyl Carbonate	5.00	Evonik, DE
	White Poetry	Fragrance	0.04	Aromatic Flavours & Fragrances Europe Ltd., GB
4	Bimiol BSC 035	Water, Caprylic / Capric Triglycerides, Pentylene Glycol, Hydrogenated Lecithin, Glycerin, Bu- tyrospermum Parkii (Shea) Butter, C12-16 Alco- hols, Palmitic Acid, Squalane, Ceramide NP	25.00	BSC Skincare Deve- lopment GmbH, DE
5	REFORCYL®	Glycerin, Water, Glutamine, Decyl Glucoside, Phenethyl Alcohol, Citric Acid, Cistus Incanus Flower/Leaf/Stem Extract, Gynostemma Pen- taphyllum Leaf/Stem Extract	3.00	RAHN AG, CH
6	L-Arginine solution 10%	Water, Arginine	5.00	Ajinomoto, JP

## Production

Mix 1 / Mix 2, add to 1 while stirring, homogenise shortly / Mix 3, add to 1/2 while stirring, homogenise / Add 4, homogenise / Add 5 while stirring, homogenise / Add 6 while stirring, homogenise.

Stability: Stable for more than 3 months at 5°, 25°, 40°, 50°C Microbiological Stability: Proven

## Disclaimer

Utilisation of this document or parts thereof as well as product names for commercial or industrial applications is subject to explicit written approval by RAHN AG. This information is based on our own experience to date and we believe it to be reliable. It is intended only as a guide to use at your discretion and risk. We cannot guarantee favourable results and we assume no liability in connection with its use, or the use of the methods or products described. None of this information is to be taken as a license to operate under, or a recommendation to infringe, patents. Version: 05/2020